Advanced search
Publication Cover
Critical Reviews in Microbiology Volume 39, 2013 - Issue 4
Submit an article Journal homepage
1,285
Views
16
CrossRef citations to date
0
Altmetric
Review Article

Animal models in virus research: their utility and limitations

Derrick LouzNational Institute for Public Health and the Environment (RIVM), GMO Office, Bilthoven, The NetherlandsCorrespondence[email protected]
,
Hans E. BergmansNational Institute for Public Health and the Environment (RIVM), GMO Office, Bilthoven, The Netherlands
,
Birgit P. LoosNational Institute for Public Health and the Environment (RIVM), Laboratory for Environmental Monitoring (LVM), Bilthoven, The Netherlands
&
Rob C. HoebenDepartment of Molecular Cell Biology, Leiden University Medical Centre, Leiden, The Netherlands
Pages 325-361 | Received 18 Mar 2012, Accepted 10 Jul 2012, Published online: 14 Sep 2012

References

  • Abbas UL, Anderson RM, Mellors JW. (2007). Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE, 2, e875.
  • Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. (2008). Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med, 358, 261–273.
  • Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329, 1168–1174.
  • Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. (2007). HIV/AIDS: in search of an animal model. Trends Biotechnol, 25, 333–337.
  • An DS, Poon B, Ho Tsong Fang R, Weijer K, Blom B, Spits H, Chen IS, Uittenbogaart CH. (2007). Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol, 14, 391–396.
  • Anderson LJ, Tong S. (2010). Update on SARS research and other possibly zoonotic coronaviruses. Int J Antimicrob Agents, 36 Suppl 1, S21–S25.
  • Anderson T, Capua I, Dauphin G, Donis R, Fouchier R, Mumford E, Peiris M, Swayne D, Thiermann A. (2010). FAO-OIE-WHO Joint Technical Consultation on Avian Influenza at the Human-Animal Interface. Influenza Other Respi Viruses, 4 Suppl 1, 1–29.
  • Apetrei C, Kaur A, Lerche NW, Metzger M, Pandrea I, Hardcastle J, Falkenstein S, Bohm R, Koehler J, Traina-Dorge V, Williams T, Staprans S, Plauche G, Veazey RS, McClure H, Lackner AA, Gormus B, Robertson DL, Marx PA. (2005). Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol, 79, 8991–9005.
  • Apetrei C, Lerche NW, Pandrea I, Gormus B, Silvestri G, Kaur A, Robertson DL, Hardcastle J, Lackner AA, Marx PA. (2006). Kuru experiments triggered the emergence of pathogenic SIVmac. AIDS, 20, 317–321.
  • Ayash-Rashkovsky M, Bentwich Z, Arditti F, Friedman S, Reisner Y, Borkow G. (2005). A novel small animal model for HIV-1 infection. FASEB J, 19, 1149–1151.
  • Baas T, Baskin CR, Diamond DL, García-Sastre A, Bielefeldt-Ohmann H, Tumpey TM, Thomas MJ, Carter VS, Teal TH, Van Hoeven N, Proll S, Jacobs JM, Caldwell ZR, Gritsenko MA, Hukkanen RR, Camp DG 2nd, Smith RD, Katze MG. (2006). Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J Virol, 80, 10813–10828.
  • Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. (2008). Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE, 3, e1401.
  • Baric RS. (2008). SARS-CoV: lessons for global health. Virus Res, 133, 1–3.
  • Baric RS, Sims AC. (2005). Humanized mice develop coronavirus respiratory disease. Proc Natl Acad Sci USA, 102, 8073–8074.
  • Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Chan PK, Sidwell RW. (2006a). Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother, 17, 275–284.
  • Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Winslow S, Hoopes J, Li JK, Lee J, Carson DA, Cottam HB, Sidwell RW. (2006b). Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res, 71, 53–63.
  • Barnard DL. (2009). Animal models for the study of influenza pathogenesis and therapy. Antiviral Res, 82, A110–A122.
  • Barnard DL, Kumaki Y. (2011). Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol, 6, 615–631.
  • Baroncelli S, Negri DR, Michelini Z, Cara A. (2008). Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines, 7, 1419–1434.
  • Barouch DH. (2008). Challenges in the development of an HIV-1 vaccine. Nature, 455, 613–619.
  • Barouch DH, Korber B. (2010). HIV-1 vaccine development after STEP. Annu Rev Med, 61, 153–167.
  • Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. (2012). Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 482, 89–93.
  • Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL. (2000). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science, 290, 486–492.
  • Barth H, Robinet E, Liang TJ, Baumert TF. (2008). Mouse models for the study of HCV infection and virus-host interactions. J Hepatol, 49, 134–142.
  • Barthold SW. (2004). Genetically altered mice: phenotypes, no phenotypes, and Faux phenotypes. Genetica, 122, 75–88.
  • Bartlam M, Xue X, Rao Z. (2008). The search for a structural basis for therapeutic intervention against the SARS coronavirus. Acta Crystallogr, A, Found Crystallogr, 64, 204–213.
  • Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, Tuthill TJ, Pedrick MS, Hurle MJ, Plumpton C, Sharp NA, Bussell JN, Swallow DM, Schwarze J, Guy B, Almond JW, Jeffery PK, Lloyd CM, Papi A, Killington RA, Rowlands DJ, Blair ED, Clarke NJ, Johnston SL. (2008). Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med, 14, 199–204.
  • Baskin CR, García-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, Nistal-Villán E, Katze MG. (2004). Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol, 78, 10420–10432.
  • Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG. (2009). Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA, 106, 3455–3460.
  • Batten CJ, De Rose R, Wilson KM, Agy MB, Chea S, Stratov I, Montefiori DC, Kent SJ. (2006). Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses, 22, 580–588.
  • Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF, Fisher EM. (2000). Genealogies of mouse inbred strains. Nat Genet, 24, 23–25.
  • Bell DM; World Health Organization Working Group on International and Community Transmission of SARS. (2004). Public health interventions and SARS spread, 2003. Emerging Infect Dis, 10, 1900–1906.
  • Belser JA, Katz JM, Tumpey TM. (2011). The ferret as a model organism to study influenza A virus infection. Dis Model Mech, 4, 575–579.
  • Benmira S, Bhattacharya V, Schmid ML. (2010). An effective HIV vaccine: A combination of humoral and cellular immunity? Curr HIV Res, 8, 441–449.
  • Bente D, Gren J, Strong JE, Feldmann H. (2009). Disease modeling for Ebola and Marburg viruses. Dis Model Mech, 2, 12–17.
  • Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. (1998). A new classification for HIV-1. Nature, 391, 240.
  • Berger EA, Murphy PM, Farber JM. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol, 17, 657–700.
  • Berger A, Drosten Ch, Doerr HW, Stürmer M, Preiser W. (2004). Severe acute respiratory syndrome (SARS)–paradigm of an emerging viral infection. J Clin Virol, 29, 13–22.
  • Berges BK, Akkina SR, Folkvord JM, Connick E, Akkina R. (2008). Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology, 373, 342–351.
  • Berges BK, Akkina SR, Remling L, Akkina R. (2010). Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology, 397, 100–103.
  • Berges BK, Rowan MR. (2011). The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology, 8, 65.
  • Berkley SF, Koff WC. (2007). Scientific and policy challenges to development of an AIDS vaccine. Lancet, 370, 94–101.
  • Bettauer RH. (2010). Chimpanzees in hepatitis C virus research: 1998-2007. J Med Primatol, 39, 9–23.
  • Bieniasz PD, Cullen BR. (2000). Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol, 74, 9868–9877.
  • Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA, 101, 6641–6646.
  • Blanco JC, Richardson JY, Darnell ME, Rowzee A, Pletneva L, Porter DD, Prince GA. (2002). Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J Infect Dis, 185, 1780–1785.
  • Blanco JC, Pletneva L, Boukhvalova M, Richardson JY, Harris KA, Prince GA. (2004). The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J Interferon Cytokine Res, 24, 21–28.
  • Boberg A, Bråve A, Johansson S, Wahren B, Hinkula J, Rollman E. (2008). Murine models for HIV vaccination and challenge. Expert Rev Vaccines, 7, 117–130.
  • Bodewes R, Rimmelzwaan GF, Osterhaus AD. (2010). Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines, 9, 59–72.
  • Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA. (2008). Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J Infect Dis, 197, 1315–1323.
  • Bontrop RE. (2001). Non-human primates: essential partners in biomedical research. Immunol Rev, 183, 5–9.
  • Bontrop RE, Watkins DI. (2005). MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol, 26, 227–233.
  • Borkow G. (2005). Mouse models for HIV-1 infection. IUBMB Life, 57, 819–823.
  • Borsetti A, Baroncelli S, Maggiorella MT, Bellino S, Moretti S, Sernicola L, Belli R, Ridolfi B, Farcomeni S, Negri DR, Cafaro A, Ensoli B, Titti F. (2008). Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch Virol, 153, 463–472.
  • Bosma GC, Custer RP, Bosma MJ. (1983). A severe combined immunodeficiency mutation in the mouse. Nature, 301, 527–530.
  • Bowen RA, Nemeth NM. (2007). Experimental infections with West Nile virus. Curr Opin Infect Dis, 20, 293–297.
  • Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, Shin HS, Brooks SF, Knight HL, Eichbaum Q, Yang YG, Sykes M, Walker BD, Freeman GJ, Pillai S, Westmoreland SV, Brander C, Luster AD, Tager AM. (2009). Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol, 83, 7305–7321.
  • Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. (2007). Transmission of influenza A in human beings. Lancet Infect Dis, 7, 257–265.
  • Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J, Burzenski L, Gott B, Foreman O, Kavirayani A, Herlihy M, Rossini AA, Shultz LD, Greiner DL. (2010). Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol, 135, 84–98.
  • Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC. (2006). Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet, 367, 1657–1664.
  • Browning J, Horner JW, Pettoello-Mantovani M, Raker C, Yurasov S, DePinho RA, Goldstein H. (1997). Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci USA, 94, 14637–14641.
  • Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 372, 1881–1893.
  • Burnet FM. (1947). Influenza virus “A” infections of cynomolgus monkeys. Aust J Exp Biol Med Sci, 19, 281–290.
  • Burns DN, Dieffenbach CW, Vermund SH. (2010). Rethinking prevention of HIV type 1 infection. Clin Infect Dis, 51, 725–731.
  • Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol, 5, 233–236.
  • Carlsson HE, Schapiro SJ, Farah I, Hau J. (2004). Use of primates in research: a global overview. Am J Primatol, 63, 225–237.
  • Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, Davies ME, McDermott AB, O’Connor DH, Fridman A, Bagchi A, Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW. (2005). Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol, 79, 15547–15555.
  • Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, Bett A, Schleif WA, Liang X, Flynn J, Tobery TW, Wilson K, Finnefrock A, Huang L, Vitelli S, Lin J, Patel D, Davies ME, Heidecker GJ, Freed DC, Dubey S, O’Connor DH, Watkins DI, Zhang ZQ, Shiver JW. (2010). Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol, 84, 2996–3003.
  • Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C. (2010). Report of an NIAID workshop on dengue animal models. Vaccine, 28, 4229–4234.
  • Chakrabarti L, Guyader M, Alizon M, Daniel MD, Desrosiers RC, Tiollais P, Sonigo P. (1987). Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature, 328, 543–547.
  • Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O’Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW. (2001). A novel influenza A virus mitochondrial protein that induces cell death. Nat Med, 7, 1306–1312.
  • Chen H, Bright RA, Subbarao K, Smith C, Cox NJ, Katz JM, Matsuoka Y. (2007a). Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Res, 128, 159–163.
  • Chen LF, Hoy J, Lewin SR. (2007b). Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust, 186, 146–151.
  • Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO. (2008a). Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog, 4, e1000072.
  • Chen Y, Liu L, Wei Q, Zhu H, Jiang H, Tu X, Qin C, Chen Z. (2008b). Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques. Virology, 381, 89–97.
  • Chen Q, Khoury M, Chen J. (2009). Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci USA, 106, 21783–21788.
  • Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR, Subbarao K. (2010). Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol, 84, 1289–1301.
  • Chen LM, Blixt O, Stevens J, Lipatov AS, Davis CT, Collins BE, Cox NJ, Paulson JC, Donis RO. (2012). In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology, 422, 105–113.
  • Cheng-Mayer C, Seto D, Tateno M, Levy JA. (1988). Biologic features of HIV-1 that correlate with virulence in the host. Science, 240, 80–82.
  • Cheng-Mayer C, Tasca S, Ho SH. (2009). Coreceptor switch in infection of nonhuman primates. Curr HIV Res, 7, 30–38.
  • Chia R, Achilli F, Festing MF, Fisher EM. (2005). The origins and uses of mouse outbred stocks. Nat Genet, 37, 1181–1186.
  • Chu YK, Ali GD, Jia F, Li Q, Kelvin D, Couch RC, Harrod KS, Hutt JA, Cameron C, Weiss SR, Jonsson CB. (2008). The SARS-CoV ferret model in an infection-challenge study. Virology, 374, 151–163.
  • Cillóniz C, Shinya K, Peng X, Korth MJ, Proll SC, Aicher LD, Carter VS, Chang JH, Kobasa D, Feldmann F, Strong JE, Feldmann H, Kawaoka Y, Katze MG. (2009). Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog, 5, e1000604.
  • Cinatl J Jr, Michaelis M, Hoever G, Preiser W, Doerr HW. (2005). Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res, 66, 81–97.
  • Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG. (1998). Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet, 351, 472–477.
  • Cline TD, Karlsson EA, Freiden P, Seufzer BJ, Rehg JE, Webby RJ, Schultz-Cherry S. (2011). Increased pathogenicity of a reassortant 2009 pandemic H1N1 influenza virus containing an H5N1 hemagglutinin. J Virol, 85, 12262–12270.
  • Cohen J. (2007). Evolutionary biology. Relative differences: the myth of 1%. Science, 316, 1836.
  • Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P. (2007). A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog, 3, 1414–1421.
  • Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. (1997). Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med, 185, 621–628.
  • Consortium CSME. (2004). Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science, 303, 1666–1669.
  • Coovadia H. (2009). Current issues in prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS, 4, 319–324.
  • Corey L, McElrath MJ. (2010). HIV vaccines: mosaic approach to virus diversity. Nat Med, 16, 268–270.
  • Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS. (2011). HIV-1 vaccines and adaptive trial designs. Sci Transl Med, 3, 79ps13.
  • Couch RB. (2008). Seasonal inactivated influenza virus vaccines. Vaccine, 26 Suppl 4, D5–D9.
  • Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M. (2008). A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog, 4, e29.
  • Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R. (2008). Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med, 5, e157; discussion e157.
  • Darnell ME, Plant EP, Watanabe H, Byrum R, St Claire M, Ward JM, Taylor DR. (2007). Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis, 196, 1329–1338.
  • Davis PH, Stanley SL Jr. (2003). Breaking the species barrier: use of SCID mouse-human chimeras for the study of human infectious diseases. Cell Microbiol, 5, 849–860.
  • Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. (2009). Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med, 360, 2605–2615.
  • Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. (2009). A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology, 395, 210–222.
  • De Clercq E. (2012). Pre-exposure chemoprophylaxis of HIV infection: Quo vadis? Biochem Pharmacol, 83, 567–573.
  • de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. (2006). Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med, 12, 1203–1207.
  • de Wit E, Kawaoka Y, de Jong MD, Fouchier RA. (2008). Pathogenicity of highly pathogenic avian influenza virus in mammals. Vaccine, 26 Suppl 4, D54–D58.
  • Dediego ML, Pewe L, Alvarez E, Rejas MT, Perlman S, Enjuanes L. (2008). Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology, 376, 379–389.
  • Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV. (2008). Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med, 5, e16.
  • Denton PW, Garcia JV. (2009). Novel humanized murine models for HIV research. Curr HIV/AIDS Rep, 6, 13–19.
  • Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, Martinez-Torres F, Zou W, Payne DA, Estes JD, Garcia JV. (2010). Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE, 5, e8829.
  • Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV. (2011). One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol, 85, 7582–7593.
  • Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, Geng J, Cai J, Han H, Li X, Kang W, Weng D, Liang P, Jiang S. (2004). Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol, 203, 622–630.
  • Doherty PC, Turner SJ, Webby RG, Thomas PG. (2006). Influenza and the challenge for immunology. Nat Immunol, 7, 449–455.
  • Doherty PC, Kelso A. (2008). Toward a broadly protective influenza vaccine. J Clin Invest, 118, 3273–3275.
  • Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. (2009a). The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol, 7, 226–236.
  • Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S. (2009b). Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology, 393, 144–150.
  • Duerr A, Wasserheit JN, Corey L. (2006). HIV vaccines: new frontiers in vaccine development. Clin Infect Dis, 43, 500–511.
  • Durbin JE, Hackenmiller R, Simon MC, Levy DE. (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell, 84, 443–450.
  • Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, Graham BS. (2002). The role of IFN in respiratory syncytial virus pathogenesis. J Immunol, 168, 2944–2952.
  • Dutta NK, Mazumdar K, Lee BH, Baek MW, Kim DJ, Na YR, Park SH, Lee HK, Kariwa H, Mai le Q, Park JH. (2008). Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine. Immunol Lett, 118, 65–71.
  • Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, Tenner-Racz K, Manson K, Wyand M, Lifton MA, Nickerson CE, Fu T, Shiver JW, Letvin NL. (2000). Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol, 74, 7485–7495.
  • Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, Friede M, Wood D. (2008). FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine, 26, 4299–4303.
  • Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R. (2008). Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res, 133, 45–62.
  • Fast PE, Kaleebu P. (2010). HIV vaccines: current status worldwide and in Africa. AIDS, 24 Suppl 4, S50–S60.
  • Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. (2008). HIV vaccine research: the way forward. Science, 321, 530–532.
  • Feinberg MB, McCune JM, Miedema F, Moore JP, Schuitemaker H. (2002). HIV tropism and CD4+ T-cell depletion. Nat Med, 8, 537.
  • Feinberg MB, Moore JP. (2002). AIDS vaccine models: challenging challenge viruses. Nat Med, 8, 207–210.
  • Fimia GM, Tripodi M, Alonzi T. (2003). Transgenic models for Hepatitis C virus pathogenesis. Cell Death Differ, 10 Suppl 1, S16–S18.
  • Finlay BB, See RH, Brunham RC. (2004). Rapid response research to emerging infectious diseases: lessons from SARS. Nat Rev Microbiol, 2, 602–607.
  • Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, Webster RG. (2009). Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine, 27, 4187–4195.
  • Forrest HL, Webster RG. (2010). Perspectives on influenza evolution and the role of research. Anim Health Res Rev, 11, 3–18.
  • Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, Peiris M, Lim W, Stöhr K, Osterhaus AD. (2003). Aetiology: Koch’s postulates fulfilled for SARS virus. Nature, 423, 240.
  • Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. (2007). Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci USA, 104, 17441–17446.
  • Friedrich TC, Watkins DI. (2008). Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr Opin HIV AIDS, 3, 393–398.
  • Frieman M, Yount B, Agnihothram S, Page C, Donaldson E, Roberts A, Vogel L, Woodruff B, Scorpio D, Subbarao K, Baric RS. (2012). Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J Virol, 86, 884–897.
  • Fruth U. (2009). Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise. Vaccine, 27, 1989–1996.
  • Gagneux P, Cheriyan M, Hurtado-Ziola N, van der Linden EC, Anderson D, McClure H, Varki A, Varki NM. (2003). Human-specific regulation of alpha 2-6-linked sialic acids. J Biol Chem, 278, 48245–48250.
  • Gao W, Tamin A, Soloff A, D’Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A. (2003). Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet, 362, 1895–1896.
  • García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W. (2008). Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med, 5, e28.
  • García-Lerma JG, Paxton L, Kilmarx PH, Heneine W. (2010). Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci, 31, 74–81.
  • Garcia-Sastre A, Whitley RJ. (2006). Lessons learned from reconstructing the 1918 influenza pandemic. J Infect Dis, 194 Suppl 2, S127–S132.
  • Gardner MB, Luciw PA. (1989). Animal models of AIDS. FASEB J, 3, 2593–2606.
  • Gardner MB, Luciw PA. (2008). Macaque models of human infectious disease. ILAR J, 49, 220–255.
  • Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. (2002). Diversity considerations in HIV-1 vaccine selection. Science, 296, 2354–2360.
  • Genescà M, Miller CJ. (2010). Use of nonhuman primate models to develop mucosal AIDS vaccines. Curr HIV/AIDS Rep, 7, 19–27.
  • Gerdts V, Littel-van den Hurk SD, Griebel PJ, Babiuk LA. (2007). Use of animal models in the development of human vaccines. Future Microbiol, 2, 667–675.
  • Geretti AM. (2006). HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis, 19, 1–7.
  • Gillim-Ross L, Subbarao K. (2006). Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev, 19, 614–636.
  • Glass WG, Subbarao K, Murphy B, Murphy PM. (2004). Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol, 173, 4030–4039.
  • Goffinet C, Michel N, Allespach I, Tervo HM, Hermann V, Kräusslich HG, Greene WC, Keppler OT. (2007). Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology, 4, 53.
  • Gorantla S, Makarov E, Finke-Dwyer J, Gebhart CL, Domm W, Dewhurst S, Gendelman HE, Poluektova LY. (2010). CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol, 184, 7082–7091.
  • Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. (2001). Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother, 45, 2723–2732.
  • Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, Hoffmann E. (2005). Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol, 79, 2191–2198.
  • Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. (2006). Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis, 194, 159–167.
  • Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. (2007). Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother, 51, 1414–1424.
  • Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG. (2009). Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother, 53, 3088–3096.
  • Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med, 363, 2587–2599.
  • Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM. (2005). Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis, 191, 507–514.
  • Griffin JF. (2002). A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery. Adv Drug Deliv Rev, 54, 851–861.
  • Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS. (2005). Multiple organ infection and the pathogenesis of SARS. J Exp Med, 202, 415–424.
  • Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL. (2003). Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science, 302, 276–278.
  • Guénet JL. (2005). Assessing the genetic component of the susceptibility of mice to viral infections. Brief Funct Genomic Proteomic, 4, 225–240.
  • Guo Y, Korteweg C, McNutt MA, Gu J. (2008). Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res, 133, 4–12.
  • Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD. (2004). Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med, 10, 290–293.
  • Haagmans BL, Osterhaus AD. (2006). Nonhuman primate models for SARS. PLoS Med, 3, e194.
  • Haaheim LR, Katz JM. (2011). Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010. Influenza Other Respi Viruses, 5, 288–295.
  • Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, Voss G, Hirsch VM, Richardson BA, Letvin NL, Hu SL, Johnson PR. (2004). Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol, 78, 5983–5995.
  • Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol, 203, 631–637.
  • Hanke T. (2008). STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev Vaccines, 7, 303–309.
  • Hatta M, Gao P, Halfmann P, Kawaoka Y. (2001). Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science, 293, 1840–1842.
  • Haut LH, Ertl HC. (2009). Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J Leukoc Biol, 86, 779–793.
  • Hayden FG, Pavia AT. (2006). Antiviral management of seasonal and pandemic influenza. J Infect Dis, 194 Suppl 2, S119–S126.
  • Hayden FG, Howard WA, Palkonyay L, Kieny MP. (2009). Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine, 27, 4079–4089.
  • Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 366, 1275–1286.
  • He B, Lin GY, Durbin JE, Durbin RK, Lamb RA. (2001). The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells. J Virol, 75, 4068–4079.
  • He Y, Zhou Y, Siddiqui P, Jiang S. (2004). Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun, 325, 445–452.
  • Heeney JL. (1996). Primate models for AIDS vaccine development. AIDS, 10 Suppl A, S115–S122.
  • Hein WR, Griebel PJ. (2003). A road less travelled: large animal models in immunological research. Nat Rev Immunol, 3, 79–84.
  • Heldens JG, Glansbeek HL, Hilgers LA, Haenen B, Stittelaar KJ, Osterhaus AD, van den Bosch JF. (2010). Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Vaccine, 28, 8125–8131.
  • Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation. (2011). Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS, 25, 679–689.
  • Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. (2012). Airborne transmission of influenza A/H5N1 virus between ferrets. Science, 336, 1534–1541.
  • Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS. (2004). Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis, 190, 1627–1630.
  • Hérodin F, Thullier P, Garin D, Drouet M. (2005). Nonhuman primates are relevant models for research in hematology, immunology and virology. Eur Cytokine Netw, 16, 104–116.
  • Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. (2009). Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med, 15, 951–954.
  • Heymann DL, Aylward RB, Wolff C. (2004). Dangerous pathogens in the laboratory: from smallpox to today’s SARS setbacks and tomorrow’s polio-free world. Lancet, 363, 1566–1568.
  • Hirst GK. (1947). Studies on the mechanism of adaptation of influenza virus to mice. J Exp Med, 86, 357–366.
  • Ho DD. (1996). Viral counts count in HIV infection. Science, 272, 1124–1125.
  • Ho O, Larsen K, Polacino P, Li Y, Anderson D, Song R, Ruprecht RM, Hu SL. (2009). Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology, 6, 65.
  • Hogan RJ, Gao G, Rowe T, Bell P, Flieder D, Paragas J, Kobinger GP, Wivel NA, Crystal RG, Boyer J, Feldmann H, Voss TG, Wilson JM. (2004). Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol, 78, 11416–11421.
  • Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D’Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M. (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet, 372, 293–299.
  • Holterman L, Niphuis H, ten Haaft PJ, Goudsmit J, Baskin G, Heeney JL. (1999). Specific passage of simian immunodeficiency virus from end-stage disease results in accelerated progression to AIDS in rhesus macaques. J Gen Virol, 80 (Pt 12), 3089–3097.
  • Horimoto T, Kawaoka Y. (2005). Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol, 3, 591–600.
  • Hota S, McGeer A. (2007). Antivirals and the control of influenza outbreaks. Clin Infect Dis, 45, 1362–1368.
  • Hsiao CH, Wu MZ, Chen CL, Hsueh PR, Hsieh SW, Yang PC, Su IJ. (2005). Evolution of pulmonary pathology in severe acute respiratory syndrome. J Formos Med Assoc, 104, 75–81.
  • Hsiung GD, Chan VF. (1989). Evaluation of new antiviral agents: II. The use of animal models. Antiviral Res, 12, 239–258.
  • Hsu M, Ho SH, Balfe P, Gettie A, Harouse J, Blanchard J, Cheng-Mayer C. (2005). A CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. J Acquir Immune Defic Syndr, 40, 383–387.
  • Hu SL. (2005). Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord, 5, 193–201.
  • Hu H, Huang X, Tao L, Huang Y, Cui BA, Wang H. (2009). Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. Vaccine, 27, 1758–1763.
  • Hui DS, Chan MC, Wu AK, Ng PC. (2004). Severe acute respiratory syndrome (SARS): epidemiology and clinical features. Postgrad Med J, 80, 373–381.
  • Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, Brown EG, Holtzman MJ, Brody SL. (2006). Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol, 80, 7469–7480.
  • Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. (2005). The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol, 79, 4460–4469.
  • Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. (2008). Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother, 52, 3889–3897.
  • Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. (2007). Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther (Lond), 12, 363–370.
  • Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le MT, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, Noda T, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y. (2010). The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. PLoS Pathog, 6, e1001106.
  • Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. (2012). Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature, 486, 420–428.
  • Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood, 106, 1565–1573.
  • Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002). NOD/SCID/gamma©(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood, 100, 3175–3182.
  • Jackson S, Van Hoeven N, Chen LM, Maines TR, Cox NJ, Katz JM, Donis RO. (2009). Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J Virol, 83, 8131–8140.
  • Javaherian K, Langlois AJ, Schmidt S, Kaufmann M, Cates N, Langedijk JP, Meloen RH, Desrosiers RC, Burns DP, Bolognesi DP. (1992). The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci USA, 89, 1418–1422.
  • Jayaraman P, Mohan D, Polacino P, Kuller L, Sheikh N, Bielefeldt-Ohmann H, Richardson B, Anderson D, Hu SL, Haigwood NL. (2004). Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina. J Med Primatol, 33, 243–250.
  • Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. (2008). Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis, 8, 650–658.
  • Jin H, Xiao C, Chen Z, Kang Y, Ma Y, Zhu K, Xie Q, Tu Y, Yu Y, Wang B. (2005). Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem Biophys Res Commun, 328, 979–986.
  • Johnson NP, Mueller J. (2002). Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med, 76, 105–115.
  • Kaiser SM, Malik HS, Emerman M. (2007). Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein. Science, 316, 1756–1758.
  • Kanki PJ, McLane MF, King NW Jr, Letvin NL, Hunt RD, Sehgal P, Daniel MD, Desrosiers RC, Essex M. (1985). Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science, 228, 1199–1201.
  • Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, García-Sastre A, Swayne DE, Katze MG. (2006). Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature, 443, 578–581.
  • Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K. (2000). Molecular correlates of influenza A H5N1 virus pathogenesis in mice. J Virol, 74, 10807–10810.
  • Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. (2006). Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science, 313, 523–526.
  • Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH. (2009a). Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature, 460, 515–519.
  • Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin NL, Mascola JR, Nabel GJ, Haynes BF, Bhattacharya T, Perelson AS, Korber BT, Hahn BH, Shaw GM. (2009b). Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med, 206, 1117–1134.
  • Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA. (2002). Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med, 195, 719–736.
  • Kijak GH, McCutchan FE. (2005). HIV diversity, molecular epidemiology, and the role of recombination. Curr Infect Dis Rep, 7, 480–488.
  • Kilmarx PH. (2009). Global epidemiology of HIV. Curr Opin HIV AIDS, 4, 240–246.
  • Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, Viscidi R, Tsai YC, He L, Chen PJ, Boyd DA, Wu TC. (2004). Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol, 78, 4638–4645.
  • King DA, Peckham C, Waage JK, Brownlie J, Woolhouse ME. (2006). Epidemiology. Infectious diseases: preparing for the future. Science, 313, 1392–1393.
  • Knight A. (2008). The beginning of the end for chimpanzee experiments? Philos Ethics Humanit Med, 3, 16.
  • Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Suzuki H, Nishimura H, Mitamura K, Sugaya N, Usui T, Murata T, Maeda Y, Watanabe S, Suresh M, Suzuki T, Suzuki Y, Feldmann H, Kawaoka Y. (2004). Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature, 431, 703–707.
  • Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M, Feldmann F, Alimonti JB, Fernando L, Li Y, Katze MG, Feldmann H, Kawaoka Y. (2007). Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature, 445, 319–323.
  • Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC. (2006). HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol, 7, 19–23.
  • Koike S, Taya C, Aoki J, Matsuda Y, Ise I, Takeda H, Matsuzaki T, Amanuma H, Yonekawa H, Nomoto A. (1994). Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene–influence of the transgene expression on pathogenesis. Arch Virol, 139, 351–363.
  • Koller BH, Smithies O. (1992). Altering genes in animals by gene targeting. Annu Rev Immunol, 10, 705–730.
  • Koup RA, Graham BS, Douek DC. (2011). The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol, 11, 65–70.
  • Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 11, 875–879.
  • Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stöhr K, Peiris JS, Osterhaus AD. (2003a). Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, 362, 263–270.
  • Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD. (2003b). Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol, 40, 304–310.
  • Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, Smith AJ, Bailey KW, Vest ZG, Madsen JR, Li JK, Barnard DL. (2011). Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res, 89, 75–82.
  • Kumlin U, Olofsson S, Dimock K, Arnberg N. (2008). Sialic acid tissue distribution and influenza virus tropism. Influenza Other Respi Viruses, 2, 147–154.
  • Kuruvilla JG, Troyer RM, Devi S, Akkina R. (2007). Dengue virus infection and immune response in humanized RAG2(-/-)gamma©(-/-) (RAG-hu) mice. Virology, 369, 143–152.
  • Lackner AA, Veazey RS. (2007). Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med, 58, 461–476.
  • Lakhashe SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC, Novembre FJ, Villinger F, Amara RR, Kahn M, Hu SL, Li S, Li Z, Frankel FR, Robert-Guroff M, Johnson WE, Lieberman J, Ruprecht RM. (2011). Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine, 29, 5611–5622.
  • Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, Subbarao K. (2008). A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol, 82, 7721–7724.
  • Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L. (2010). Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase ½ trial in adults. J Infect Dis, 201, 1644–1653.
  • Lassnig C, Sanchez CM, Egerbacher M, Walter I, Majer S, Kolbe T, Pallares P, Enjuanes L, Müller M. (2005). Development of a transgenic mouse model susceptible to human coronavirus 229E. Proc Natl Acad Sci USA, 102, 8275–8280.
  • Lawler JV, Endy TP, Hensley LE, Garrison A, Fritz EA, Lesar M, Baric RS, Kulesh DA, Norwood DA, Wasieloski LP, Ulrich MP, Slezak TR, Vitalis E, Huggins JW, Jahrling PB, Paragas J. (2006). Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med, 3, e149.
  • Lee CW, Saif YM. (2009). Avian influenza virus. Comp Immunol Microbiol Infect Dis, 32, 301–310.
  • Legrand N, Weijer K, Spits H. (2006). Experimental models to study development and function of the human immune system in vivo. J Immunol, 176, 2053–2058.
  • Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, Debarry J, de Jong Y, Deng H, Di Santo JP, Eisenbarth S, Eynon E, Flavell RA, Guzman CA, Huntington ND, Kremsdorf D, Manns MP, Manz MG, Mention JJ, Ott M, Rathinam C, Rice CM, Rongvaux A, Stevens S, Spits H, Strick-Marchand H, Takizawa H, van Lent AU, Wang C, Weijer K, Willinger T, Ziegler P. (2009). Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe, 6, 5–9.
  • Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM. (2003). Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA, 100, 6588–6592.
  • Leonard JM, Abramczuk JW, Pezen DS, Rutledge R, Belcher JH, Hakim F, Shearer G, Lamperth L, Travis W, Fredrickson T. (1988). Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science, 242, 1665–1670.
  • Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G. (2007). Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet, 370, 580–589.
  • Leroux-Roels I, Leroux-Roels G. (2009). Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines, 8, 401–423.
  • Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, Xu L, Yang ZY, Chakrabarti B, Rao SS, Schmitz JE, Montefiori DC, Barker BR, Bookstein FL, Nabel GJ. (2006). Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science, 312, 1530–1533.
  • Letvin NL. (2007). Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity, 27, 366–369.
  • Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426, 450–454.
  • Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. (2005a). Bats are natural reservoirs of SARS-like coronaviruses. Science, 310, 676–679.
  • Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC, Zhong N, Lu PY. (2005b). Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med, 11, 944–951.
  • Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G, Kawaoka Y. (2010). Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci USA, 107, 4687–4692.
  • Liang G, Chen Q, Xu J, Liu Y, Lim W, Peiris JS, Anderson LJ, Ruan L, Li H, Kan B, Di B, Cheng P, Chan KH, Erdman DD, Gu S, Yan X, Liang W, Zhou D, Haynes L, Duan S, Zhang X, Zheng H, Gao Y, Tong S, Li D, Fang L, Qin P, Xu W; SARS Diagnosis Working Group. (2004). Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerging Infect Dis, 10, 1774–1781.
  • Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW. (2005). Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol, 79, 12321–12331.
  • Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, Chen X, Liu YX, Gao H, Jia YP, Liu Y, Sun RH, Wang X, Yu DZ, Hai R, Gao Q, Ning Y, Wang HX, Li MC, Kan B, Dong GM, An Q, Wang YQ, Han J, Qin C, Yin WD, Dongs XP. (2007). Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther (Lond), 12, 1107–1113.
  • Liu BH, Wu DL, Zhan DW, Qin ED, Zhu QY, Wang CE, Meng QW, Peng WM, Yin XN, Yang YH, Guan YT, Han WG, Li CW, Liu YG, Wang MP, Liu QG, Shi HY, Ding ZF. (2004). [Study on the animal model for severe acute respiratory syndrome]. Wei Sheng Wu Xue Bao, 44, 711–716.
  • Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. (2009). Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature, 457, 87–91.
  • Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI. (2007). Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol, 81, 8827–8832.
  • Lorenzo G, Martín-Folgar R, Hevia E, Boshra H, Brun A. (2010). Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine, 28, 2937–2944.
  • Louz D, Bergmans HE, Loos BP, Hoeben RC. (2005). Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines. J Gene Med, 7, 1263–1274.
  • Louz D, Bergmans HE, Loos BP, Hoeben RC. (2010). Emergence of viral diseases: mathematical modeling as a tool for infection control, policy and decision making. Crit Rev Microbiol, 36, 195–211.
  • Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. (1999). A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol, 73, 5903–5911.
  • Maher JA, DeStefano J. (2004). The ferret: an animal model to study influenza virus. Lab Anim (NY), 33, 50–53.
  • Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM. (2005). Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol, 79, 11788–11800.
  • Maines TR, Chen LM, Matsuoka Y, Chen H, Rowe T, Ortin J, Falcón A, Nguyen TH, Mai le Q, Sedyaningsih ER, Harun S, Tumpey TM, Donis RO, Cox NJ, Subbarao K, Katz JM. (2006). Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci USA, 103, 12121–12126.
  • Maines TR, Chen LM, Belser JA, Van Hoeven N, Smith E, Donis RO, Tumpey TM, Katz JM. (2011a). Multiple genes contribute to the virulent phenotype observed in ferrets of an H5N1 influenza virus isolated from Thailand in 2004. Virology, 413, 226–230.
  • Maines TR, Chen LM, Van Hoeven N, Tumpey TM, Blixt O, Belser JA, Gustin KM, Pearce MB, Pappas C, Stevens J, Cox NJ, Paulson JC, Raman R, Sasisekharan R, Katz JM, Donis RO. (2011b). Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology, 413, 139–147.
  • Mak TW, Penninger JM, Ohashi PS. (2001). Knockout mice: a paradigm shift in modern immunology. Nat Rev Immunol, 1, 11–19.
  • Manchester M, Rall GF. (2001). Model Systems: transgenic mouse models for measles pathogenesis. Trends Microbiol, 9, 19–23.
  • Manz MG. (2007). Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity, 26, 537–541.
  • Manz MG, Di Santo JP. (2009). Renaissance for mouse models of human hematopoiesis and immunobiology. Nat Immunol, 10, 1039–1042.
  • Mariani R, Rutter G, Harris ME, Hope TJ, Kräusslich HG, Landau NR. (2000). A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol, 74, 3859–3870.
  • Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. (2003). The Genome sequence of the SARS-associated coronavirus. Science, 300, 1399–1404.
  • Marsh M, Helenius A. (2006). Virus entry: open sesame. Cell, 124, 729–740.
  • Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS; VRC 301 Study Team. (2008). A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine, 26, 6338–6343.
  • Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Peiris JS, Lim W, Osterhaus AD. (2003). Virology: SARS virus infection of cats and ferrets. Nature, 425, 915.
  • Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. (1999). Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol, 73, 4009–4018.
  • Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR, Donatelli I, Kawaoka Y. (2000). Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol, 74, 8502–8512.
  • McAuliffe J, Vogel L, Roberts A, Fahle G, Fischer S, Shieh WJ, Butler E, Zaki S, St Claire M, Murphy B, Subbarao K. (2004). Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology, 330, 8–15.
  • McBurney SP, Ross TM. (2008). Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines, 7, 1405–1417.
  • McCray PB Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, Meyerholz DK, Kirby P, Look DC, Perlman S. (2007). Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol, 81, 813–821.
  • McCutchan FE. (2006). Global epidemiology of HIV. J Med Virol, 78 Suppl 1, S7–S12.
  • McDermott AB, O’Connor DH, Fuenger S, Piaskowski S, Martin S, Loffredo J, Reynolds M, Reed J, Furlott J, Jacoby T, Riek C, Dodds E, Krebs K, Davies ME, Schleif WA, Casimiro DR, Shiver JW, Watkins DI. (2005). Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J Virol, 79, 15556–15566.
  • McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team. (2008). HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet, 372, 1894–1905.
  • McElrath MJ, Haynes BF. (2010). Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity, 33, 542–554.
  • Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, Wege AK, Haase AT, Garcia JV. (2006). Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med, 12, 1316–1322.
  • Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84, 431–442.
  • Mestas J, Hughes CC. (2004). Of mice and not men: differences between mouse and human immunology. J Immunol, 172, 2731–2738.
  • Meunier I, Pillet S, Simonsen JN, von Messling V. (2010). Influenza pathogenesis: lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit Care Med, 38, e21–e29.
  • Middleton D, Rockman S, Pearse M, Barr I, Lowther S, Klippel J, Ryan D, Brown L. (2009). Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol, 83, 7770–7778.
  • Miyoshi-Akiyama T, Ishida I, Fukushi M, Yamaguchi K, Matsuoka Y, Ishihara T, Tsukahara M, Hatakeyama S, Itoh N, Morisawa A, Yoshinaka Y, Yamamoto N, Lianfeng Z, Chuan Q, Kirikae T, Sasazuki T. (2011). Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. J Infect Dis, 203, 1574–1581.
  • Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. (1992). RAG-1-deficient mice have no mature B and T lymphocytes. Cell, 68, 869–877.
  • Montagnier L. (2010). 25 years after HIV discovery: prospects for cure and vaccine. Virology, 397, 248–254.
  • Monto AS. (2006). Vaccines and antiviral drugs in pandemic preparedness. Emerging Infect Dis, 12, 55–60.
  • Monto AS. (2009). The risk of seasonal and pandemic influenza: prospects for control. Clin Infect Dis, 48 Suppl 1, S20–S25.
  • Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. (2000). Clinical signs and symptoms predicting influenza infection. Arch Intern Med, 160, 3243–3247.
  • Monto AS, Whitley RJ. (2008). Seasonal and pandemic influenza: a 2007 update on challenges and solutions. Clin Infect Dis, 46, 1024–1031.
  • Morens DM, Fauci AS. (2007). The 1918 influenza pandemic: insights for the 21st century. J Infect Dis, 195, 1018–1028.
  • Morens DM, Taubenberger JK, Fauci AS. (2008). Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis, 198, 962–970.
  • Morens DM, Subbarao K, Taubenberger JK. (2012). Engineering H5N1 avian influenza viruses to study human adaptation. Nature, 486, 335–340.
  • Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L. (2008). The use of nonhuman primate models in HIV vaccine development. PLoS Med, 5, e173.
  • Mota J, Rico-Hesse R. (2009). Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol, 83, 8638–8645.
  • Mothé BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, Allison DB, Watkins DI. (2003). Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol, 77, 2736–2740.
  • Muchmore EA. (2001). Chimpanzee models for human disease and immunobiology. Immunol Rev, 183, 86–93.
  • Müller I, Garcia-Sanz JA, Titus R, Behin R, Louis J. (1989). Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major. Immunol Rev, 112, 95–113.
  • Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Nidom CA, Mai le Q, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. (2008). Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine, 26, 6398–6404.
  • Murphy BR, Hinshaw VS, Sly DL, London WT, Hosier NT, Wood FT, Webster RG, Chanock RM. (1982). Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun, 37, 1119–1126.
  • Murphy FA. (2008). Emerging zoonoses: the challenge for public health and biodefense. Prev Vet Med, 86, 216–223.
  • Nagata N, Iwata N, Hasegawa H, Sato Y, Morikawa S, Saijo M, Itamura S, Saito T, Ami Y, Odagiri T, Tashiro M, Sata T. (2007). Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes. Int J Exp Pathol, 88, 403–414.
  • Nagata N, Iwata N, Hasegawa H, Fukushi S, Harashima A, Sato Y, Saijo M, Taguchi F, Morikawa S, Sata T. (2008). Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol, 172, 1625–1637.
  • Nagata N, Iwata-Yoshikawa N, Taguchi F. (2010). Studies of severe acute respiratory syndrome coronavirus pathology in human cases and animal models. Vet Pathol, 47, 881–892.
  • Narasaraju T, Sim MK, Ng HH, Phoon MC, Shanker N, Lal SK, Chow VT. (2009). Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis. Microbes Infect, 11, 2–11.
  • Nath BM, Schumann KE, Boyer JD. (2000). The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol, 8, 426–431.
  • Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. (2008). Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol, 82, 7264–7275.
  • Netland J, DeDiego ML, Zhao J, Fett C, Alvarez E, Nieto-Torres JL, Enjuanes L, Perlman S. (2010). Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology, 399, 120–128.
  • Neumann G, Noda T, Kawaoka Y. (2009). Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature, 459, 931–939.
  • Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y. (2010). H5N1 influenza viruses: outbreaks and biological properties. Cell Res, 20, 51–61.
  • Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS. (2008). Evolving complexities of influenza virus and its receptors. Trends Microbiol, 16, 149–157.
  • Niewiesk S, Prince G. (2002). Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim, 36, 357–372.
  • Nilsson C, Mäkitalo B, Thorstensson R, Norley S, Binninger-Schinzel D, Cranage M, Rud E, Biberfeld G, Putkonen P. (1998). Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS, 12, 2261–2270.
  • Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, Goeken RM, Goldstein S, Hirsch VM, Martin MA. (2004). Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA, 101, 12324–12329.
  • Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Höschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC. (2008). Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine, 26, 4160–4167.
  • Nomaguchi M, Doi N, Kamada K, Adachi A. (2008). Species barrier of HIV-1 and its jumping by virus engineering. Rev Med Virol, 18, 261–275.
  • Normile D. (2004). Severe acute respiratory syndrome: lab accidents prompt calls for new containment program. Science, 304, 1223–1225.
  • Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O’Neil SP, Brown CR 2nd, Hart CE, Guenthner PC, Swenson RB, McClure HM. (1997). Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol, 71, 4086–4091.
  • O’Donnell CD, Subbarao K. (2011). The contribution of animal models to the understanding of the host range and virulence of influenza A viruses. Microbes Infect, 13, 502–515.
  • O’Neil SP, Novembre FJ, Hill AB, Suwyn C, Hart CE, Evans-Strickfaden T, Anderson DC, deRosayro J, Herndon JG, Saucier M, McClure HM. (2000). Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis, 182, 1051–1062.
  • Olesen R, Wahl A, Denton PW, Garcia JV. (2011). Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol, 88, 195–203.
  • Osterhaus AD. (2007). Pre- or post-pandemic influenza vaccine? Vaccine, 25, 4983–4984.
  • Ottolini MG, Blanco JC, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA. (2005). The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol, 86, 2823–2830.
  • Padian NS, McCoy SI, Balkus JE, Wasserheit JN. (2010). Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS, 24, 621–635.
  • Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G. (2002). ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol, 76, 292–302.
  • Palache B, Krause R. (2009). Progress with human H5N1 vaccines: a perspective from industry. Expert Rev Vaccines, 8, 391–400.
  • Palese P, Tumpey TM, Garcia-Sastre A. (2006). What can we learn from reconstructing the extinct 1918 pandemic influenza virus? Immunity, 24, 121–124.
  • Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP. (2009). HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis, 48, 806–815.
  • Pandrea I, Sodora DL, Silvestri G, Apetrei C. (2008). Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol, 29, 419–428.
  • Pang H, Liu Y, Han X, Xu Y, Jiang F, Wu D, Kong X, Bartlam M, Rao Z. (2004). Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol, 85, 3109–3113.
  • Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U.S. Public Health Service. (2005). Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep, 54, 1–17.
  • Pantaleo G, Graziosi C, Fauci AS. (1993). New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med, 328, 327–335.
  • Pappas C, Aguilar PV, Basler CF, Solórzano A, Zeng H, Perrone LA, Palese P, García-Sastre A, Katz JM, Tumpey TM. (2008). Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci USA, 105, 3064–3069.
  • Parrish CR, Kawaoka Y. (2005). The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu Rev Microbiol, 59, 553–586.
  • Parrish CR, Holmes EC, Morens DM, Park EC, Burke DS, Calisher CH, Laughlin CA, Saif LJ, Daszak P. (2008). Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev, 72, 457–470.
  • Pearson T, Greiner DL, Shultz LD. (2008). Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol, 324, 25–51.
  • Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. (2003). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet, 361, 1767–1772.
  • Peiris JS, de Jong MD, Guan Y. (2007). Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev, 20, 243–267.
  • Peiris JS, Cheung CY, Leung CY, Nicholls JM. (2009). Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol, 30, 574–584.
  • Perlman S, Netland J. (2009). Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol, 7, 439–450.
  • Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M. (2008). Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol, 80, 565–576.
  • Perrin L, Kaiser L, Yerly S. (2003). Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis, 3, 22–27.
  • Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM. (2008). H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog, 4, e1000115.
  • Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F. (2009). A new human immunodeficiency virus derived from gorillas. Nat Med, 15, 871–872.
  • Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC. (2006). Interferon-inducible Mx gene expression in cotton rats: cloning, characterization, and expression during influenza viral infection. J Interferon Cytokine Res, 26, 914–921.
  • Plotkin SA. (2008). Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis, 47, 401–409.
  • Polacino P, Larsen K, Galmin L, Suschak J, Kraft Z, Stamatatos L, Anderson D, Barnett SW, Pal R, Bost K, Bandivdekar AH, Miller CJ, Hu SL. (2008). Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J Med Primatol, 37 Suppl 2, 13–23.
  • Poland GA, Sambhara S. (2008). Vaccines against influenza A (H5N1): evidence of progress. J Infect Dis, 198, 629–631.
  • Poon LL, Guan Y, Nicholls JM, Yuen KY, Peiris JS. (2004). The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis, 4, 663–671.
  • Pope M, Haase AT. (2003). Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med, 9, 847–852.
  • Poutanen SM, McGeer AJ. (2004). Transmission and Control of SARS. Curr Infect Dis Rep, 6, 220–227.
  • Qi L, Kash JC, Dugan VG, Wang R, Jin G, Cunningham RE, Taubenberger JK. (2009). Role of sialic acid binding specificity of the 1918 influenza virus hemagglutinin protein in virulence and pathogenesis for mice. J Virol, 83, 3754–3761.
  • Qin C, Wang J, Wei Q, She M, Marasco WA, Jiang H, Tu X, Zhu H, Ren L, Gao H, Guo L, Huang L, Yang R, Cong Z, Guo L, Wang Y, Liu Y, Sun Y, Duan S, Qu J, Chen L, Tong W, Ruan L, Liu P, Zhang H, Zhang J, Zhang H, Liu D, Liu Q, Hong T, He W. (2005). An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol, 206, 251–259.
  • Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ. (2012). Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol, 86, 2239–2250.
  • Rämer PC, Chijioke O, Meixlsperger S, Leung CS, Münz C. (2011). Mice with human immune system components as in vivo models for infections with human pathogens. Immunol Cell Biol, 89, 408–416.
  • Randall RE, Goodbourn S. (2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol, 89, 1–47.
  • Reid AH, Janczewski TA, Lourens RM, Elliot AJ, Daniels RS, Berry CL, Oxford JS, Taubenberger JK. (2003). 1918 influenza pandemic caused by highly conserved viruses with two receptor-binding variants. Emerging Infect Dis, 9, 1249–1253.
  • Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL. (1996). A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol, 70, 6922–6928.
  • Reimann KA, Parker RA, Seaman MS, Beaudry K, Beddall M, Peterson L, Williams KC, Veazey RS, Montefiori DC, Mascola JR, Nabel GJ, Letvin NL. (2005). Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol, 79, 8878–8885.
  • Ren R, Racaniello VR. (1992). Human poliovirus receptor gene expression and poliovirus tissue tropism in transgenic mice. J Virol, 66, 296–304.
  • Renegar KB. (1992). Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci, 42, 222–232.
  • Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 361, 2209–2220.
  • Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI. (2012). A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine, 30, 4465–4475.
  • Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. (2009). The challenge of finding a cure for HIV infection. Science, 323, 1304–1307.
  • Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. (2001). A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine, 20, 158–163.
  • Rivera J, Tessarollo L. (2008). Genetic background and the dilemma of translating mouse studies to humans. Immunity, 28, 1–4.
  • Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K. (2005). Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol, 79, 5833–5838.
  • Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S, Subbarao K. (2005). Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol, 79, 503–511.
  • Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM. (2006). Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis, 193, 685–692.
  • Roberts A, Wood J, Subbarao K, Ferguson M, Wood D, Cherian T. (2006). Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK. Vaccine, 24, 7056–7065.
  • Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. (2007). A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog, 3, e5.
  • Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K. (2008). Animal models and vaccines for SARS-CoV infection. Virus Res, 133, 20–32.
  • Roberts A, Lamirande EW, Vogel L, Baras B, Goossens G, Knott I, Chen J, Ward JM, Vassilev V, Subbarao K. (2010). Immunogenicity and protective efficacy in mice and hamsters of a ß-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol, 23, 509–519.
  • Robinson HL. (2007). HIV/AIDS vaccines: 2007. Clin Pharmacol Ther, 82, 686–693.
  • Rockx B, Sheahan T, Donaldson E, Harkema J, Sims A, Heise M, Pickles R, Cameron M, Kelvin D, Baric R. (2007). Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J Virol, 81, 7410–7423.
  • Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, Dyer MD, Teal TH, Proll S, van den Brand J, Baric R, Katze MG. (2009). Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol, 83, 7062–7074.
  • Rockx B, Feldmann F, Brining D, Gardner D, LaCasse R, Kercher L, Long D, Rosenke R, Virtaneva K, Sturdevant DE, Porcella SF, Mattoon J, Parnell M, Baric RS, Feldmann H. (2011). Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PLoS ONE, 6, e18558.
  • Roper RL, Rehm KE. (2009). SARS vaccines: where are we? Expert Rev Vaccines, 8, 887–898.
  • Ross AL, Bråve A, Scarlatti G, Manrique A, Buonaguro L. (2010). Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis, 10, 305–316.
  • Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Peñaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Günther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 300, 1394–1399.
  • Rowe T, Gao G, Hogan RJ, Crystal RG, Voss TG, Grant RL, Bell P, Kobinger GP, Wivel NA, Wilson JM. (2004). Macaque model for severe acute respiratory syndrome. J Virol, 78, 11401–11404.
  • Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. (2008). Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol, 82, 2565–2569.
  • Rutjens E, Balla-Jhagjhoorsingh S, Verschoor E, Bogers W, Koopman G, Heeney J. (2003). Lentivirus infections and mechanisms of disease resistance in chimpanzees. Front Biosci, 8, d1134–d1145.
  • Sabarth N, Howard MK, Savidis-Dacho H, van Maurik A, Barrett PN, Kistner O. (2010). Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine, 28, 650–656.
  • Sallé B, Brochard P, Bourry O, Mannioui A, Andrieu T, Prevot S, Dejucq-Rainsford N, Dereuddre-Bosquet N, Le Grand R. (2010). Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis, 202, 337–344.
  • Salomon R, Webster RG. (2009). The influenza virus enigma. Cell, 136, 402–410.
  • Sato K, Nie C, Misawa N, Tanaka Y, Ito M, Koyanagi Y. (2010). Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. Vaccine, 28 Suppl 2, B32–B37.
  • Sawada S, Gowrishankar K, Kitamura R, Suzuki M, Suzuki G, Tahara S, Koito A. (1998). Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med, 187, 1439–1449.
  • Schaecher SR, Stabenow J, Oberle C, Schriewer J, Buller RM, Sagartz JE, Pekosz A. (2008). An immunosuppressed Syrian golden hamster model for SARS-CoV infection. Virology, 380, 312–321.
  • Schildgen O, Simon A, Williams J. (2007). Animal models for human metapneumovirus (HMPV) infections. Vet Res, 38, 117–126.
  • Scholtissek C, Rohde W, Von Hoyningen V, Rott R. (1978). On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology, 87, 13–20.
  • Schröfelbauer B, Chen D, Landau NR. (2004). A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA, 101, 3927–3932.
  • See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB. (2006). Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol, 87, 641–650.
  • See RH, Petric M, Lawrence DJ, Mok CP, Rowe T, Zitzow LA, Karunakaran KP, Voss TG, Brunham RC, Gauldie J, Finlay BB, Roper RL. (2008). Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J Gen Virol, 89, 2136–2146.
  • Sekaly RP. (2008). The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med, 205, 7–12.
  • Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Wyatt L, Carroll M, Moss B, Venzon D, Letvin NL, Hirsch VM. (2000). Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol, 74, 2502–2509.
  • Shacklett BL. (2008). Can the new humanized mouse model give HIV research a boost. PLoS Med, 5, e13.
  • Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS. (2011). Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol, 85, 217–230.
  • Shedlock DJ, Silvestri G, Weiner DB. (2009). Monkeying around with HIV vaccines: using rhesus macaques to define ‘gatekeepers’ for clinical trials. Nat Rev Immunol, 9, 717–728.
  • Shi Z, Hu Z. (2008). A review of studies on animal reservoirs of the SARS coronavirus. Virus Res, 133, 74–87.
  • Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. (1999). Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med, 5, 204–210.
  • Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. (2006). Avian flu: influenza virus receptors in the human airway. Nature, 440, 435–436.
  • Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. (2004). PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology, 320, 258–266.
  • Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 415, 331–335.
  • Shultz LD, Ishikawa F, Greiner DL. (2007). Humanized mice in translational biomedical research. Nat Rev Immunol, 7, 118–130.
  • Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F. (2010). Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci USA, 107, 13022–13027.
  • Sibal LR, Samson KJ. (2001). Nonhuman primates: a critical role in current disease research. ILAR J, 42, 74–84.
  • Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, Lakhashe S, Santosuosso M, Poznansky MC, Novembre FJ, Villinger F, Else JG, Montefiori DC, Rasmussen RA, Ruprecht RM. (2010). R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS ONE, 5, e11689.
  • Siddappa NB, Hemashettar G, Wong YL, Lakhashe S, Rasmussen RA, Watkins JD, Novembre FJ, Villinger F, Else JG, Montefiori DC, Ruprecht RM. (2011). Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunosprophylaxis. J Med Primatol, 40, 120–128.
  • Sidwell RW, Smee DF. (2000). In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res, 48, 1–16.
  • Smith H, Sweet C. (1988). Lessons for human influenza from pathogenicity studies with ferrets. Rev Infect Dis, 10, 56–75.
  • Smith JM, Dauner A, Li B, Srinivasan P, Mitchell J, Hendry M, Ellenberger D, Butera S, Otten RA. (2010). Generation of a dual RT Env SHIV that is infectious in rhesus macaques. J Med Primatol, 39, 213–223.
  • Smith JR. (2010). Oseltamivir in human avian influenza infection. J Antimicrob Chemother, 65 Suppl 2, ii25–ii33.
  • Smits SL, de Lang A, van den Brand JM, Leijten LM, van IJcken WF, Eijkemans MJ, van Amerongen G, Kuiken T, Andeweg AC, Osterhaus AD, Haagmans BL. (2010). Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog, 6, e1000756.
  • Smits SL, van den Brand JM, de Lang A, Leijten LM, van Ijcken WF, van Amerongen G, Osterhaus AD, Andeweg AC, Haagmans BL. (2011). Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J Virol, 85, 4234–4245.
  • Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL, Guan Y, Rozanov M, Spaan WJ, Gorbalenya AE. (2003). Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol, 331, 991–1004.
  • Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, Chen QX, Gao YW, Zhou HQ, Xiang H, Zheng HJ, Chern SW, Cheng F, Pan CM, Xuan H, Chen SJ, Luo HM, Zhou DH, Liu YF, He JF, Qin PZ, Li LH, Ren YQ, Liang WJ, Yu YD, Anderson L, Wang M, Xu RH, Wu XW, Zheng HY, Chen JD, Liang G, Gao Y, Liao M, Fang L, Jiang LY, Li H, Chen F, Di B, He LJ, Lin JY, Tong S, Kong X, Du L, Hao P, Tang H, Bernini A, Yu XJ, Spiga O, Guo ZM, Pan HY, He WZ, Manuguerra JC, Fontanet A, Danchin A, Niccolai N, Li YX, Wu CI, Zhao GP. (2005). Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA, 102, 2430–2435.
  • Srivastava B, Blazejewska P, Hessmann M, Bruder D, Geffers R, Mauel S, Gruber AD, Schughart K. (2009). Host genetic background strongly influences the response to influenza a virus infections. PLoS ONE, 4, e4857.
  • Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O. (1988). Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol, 8, 4518–4523.
  • Staprans SI, Feinberg MB. (2004). The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines, 3, S5–32.
  • Staprans SI, Feinberg MB, Shiver JW, Casimiro DR. (2010). Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Curr Opin HIV AIDS, 5, 377–385.
  • Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA. (2006). Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol, 355, 1143–1155.
  • Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, Wilson IA. (2008). Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol, 381, 1382–1394.
  • Stockman LJ, Bellamy R, Garner P. (2006). SARS: systematic review of treatment effects. PLoS Med, 3, e343.
  • Stremlau M. (2007). GE Prize-winning essay. Why Old World monkeys are resistant to HIV-1. Science, 318, 1565–1566.
  • Strickland SL, Gray RR, Lamers SL, Burdo TH, Huenink E, Nolan DJ, Nowlin B, Alvarez X, Midkiff CC, Goodenow MM, Williams K, Salemi M. (2011). Significant genetic heterogeneity of the SIVmac251 viral swarm derived from different sources. AIDS Res Hum Retroviruses, 27, 1327–1332.
  • Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N. (1998). Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science, 279, 393–396.
  • Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B. (2004). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol, 78, 3572–3577.
  • Subbarao K, Roberts A. (2006). Is there an ideal animal model for SARS? Trends Microbiol, 14, 299–303.
  • Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V, Rendon A, Hudgens MG, Butera S, Janssen R, Paxton L, Greenberg AE, Folks TM. (2006). Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis, 194, 904–911.
  • Subbarao K, Luke C. (2007). H5N1 viruses and vaccines. PLoS Pathog, 3, e40.
  • Subbarao K, Joseph T. (2007). Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol, 7, 267–278.
  • Sullivan M. (2009). Moving candidate vaccines into development from research: lessons from HIV. Immunol Cell Biol, 87, 366–370.
  • Sun J, Soos T, Kewalramani VN, Osiecki K, Zheng JH, Falkin L, Santambrogio L, Littman DR, Goldstein H. (2006). CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate. J Virol, 80, 1850–1862.
  • Tan RC, Harouse JM, Gettie A, Cheng-Mayer C. (1999). In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein. J Med Primatol, 28, 164–168.
  • Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. (2010). A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis, 4, e672.
  • Tang Q, Li B, Woodle M, Lu PY. (2008). Application of siRNA against SARS in the rhesus macaque model. Methods Mol Biol, 442, 139–158.
  • Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. (2005). Characterization of the 1918 influenza virus polymerase genes. Nature, 437, 889–893.
  • Taubenberger JK, Morens DM. (2006). 1918 Influenza: the mother of all pandemics. Emerging Infect Dis, 12, 15–22.
  • Taubenberger JK, Morens DM. (2008). The pathology of influenza virus infections. Annu Rev Pathol, 3, 499–522.
  • Taylor DR. (2006). Obstacles and advances in SARS vaccine development. Vaccine, 24, 863–871.
  • Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. (2008). The challenge of HIV-1 subtype diversity. N Engl J Med, 358, 1590–1602.
  • ten Haaft P, Almond N, Biberfeld G, Cafaro A, Cranage M, Ensoli B, Hunsmann G, Polyanskaya N, Stahl-Hennig C, Thortensson R, Titti F, Heeney J. (2001). Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J Med Primatol, 30, 207–214.
  • ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD. (2004). Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet, 363, 2139–2141.
  • Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. (2006). Cell-mediated protection in influenza infection. Emerging Infect Dis, 12, 48–54.
  • Thomas C. (2009). Roadblocks in HIV research: five questions. Nat Med, 15, 855–859.
  • Trammell RA, Toth LA. (2008). Genetic susceptibility and resistance to influenza infection and disease in humans and mice. Expert Rev Mol Diagn, 8, 515–529.
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med, 354, 1343–1351.
  • Tsang K, Seto WH. (2004). Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. Curr Opin Investig Drugs, 5, 179–185.
  • Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, Wong PC, Lam B, Ip MS, Chan J, Yuen KY, Lai KN. (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 348, 1977–1985.
  • Tseng CT, Huang C, Newman P, Wang N, Narayanan K, Watts DM, Makino S, Packard MM, Zaki SR, Chan TS, Peters CJ. (2007). Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol, 81, 1162–1173.
  • Tsui PT, Kwok ML, Yuen H, Lai ST. (2003). Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerging Infect Dis, 9, 1064–1069.
  • Tumpey TM, García-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P, Basler CF. (2002). Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA, 99, 13849–13854.
  • Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swayne DE, Basler CF. (2004). Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA, 101, 3166–3171.
  • Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solórzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, García-Sastre A. (2005a). Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science, 310, 77–80.
  • Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood MJ, Schultz-Cherry S, Solórzano A, Van Rooijen N, Katz JM, Basler CF. (2005b). Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol, 79, 14933–14944.
  • Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solórzano A, Pappas C, Cox NJ, Swayne DE, Palese P, Katz JM, García-Sastre A. (2007). A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science, 315, 655–659.
  • Uberla K. (2005). Efficacy of AIDS vaccine strategies in nonhuman primates. Med Microbiol Immunol, 194, 201–206.
  • Uyeki TM. (2009). Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis, 49, 279–290.
  • Vaccari M, Poonam P, Franchini G. (2010). Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines, 9, 997–1005.
  • Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, Mbanya D, Kaptué L, Ndembi N, Gürtler L, Devare S, Brennan CA. (2011). Confirmation of putative HIV-1 group P in Cameroon. J Virol, 85, 1403–1407.
  • van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. (2008). Animal models in influenza vaccine testing. Expert Rev Vaccines, 7, 783–793.
  • Van Hoeven N, Pappas C, Belser JA, Maines TR, Zeng H, García-Sastre A, Sasisekharan R, Katz JM, Tumpey TM. (2009). Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci USA, 106, 3366–3371.
  • van Maanen M, Sutton RE. (2003). Rodent models for HIV-1 infection and disease. Curr HIV Res, 1, 121–130.
  • van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. (2006). H5N1 Virus Attachment to Lower Respiratory Tract. Science, 312, 399.
  • van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. (2007). Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol, 171, 1215–1223.
  • Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML. (2001). Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis, 184, 429–438.
  • Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, Earl P, Harvey D, Franchini G, Tartaglia J, Montefiori D, Hattangadi S, Moss B, Marthas ML. (2005). Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr, 38, 124–134.
  • Van Rompay KK. (2010). Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res, 85, 159–175.
  • Veazey RS. (2008). Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS, 3, 567–573.
  • Veronese F, Turpin JA, Feuer C. (2010). Beyond 2010: Gaps, Challenges, and Priorities for the Future of Preclinical HIV Preexposure Prophylaxis (PrEP): Summary of the October 20–21, 2009 Workshop. AIDS Res Hum Retroviruses.
  • Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D; Workshop Organizing Committee. (2011). Implications of HIV PrEP trials results. AIDS Res Hum Retroviruses, 27, 81–90.
  • Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. (1995). Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol, 155, 3946–3954.
  • Vogel LN, Roberts A, Paddock CD, Genrich GL, Lamirande EW, Kapadia SU, Rose JK, Zaki SR, Subbarao K. (2007). Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine, 25, 2173–2179.
  • Walker BD, Burton DR. (2008). Toward an AIDS vaccine. Science, 320, 760–764.
  • Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. (2008). Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med, 14, 617–621.
  • Webby R, Hoffmann E, Webster R. (2004). Molecular constraints to interspecies transmission of viral pathogens. Nat Med, 10, S77–S81.
  • Weiss SR, Navas-Martin S. (2005). Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev, 69, 635–664.
  • Whetter LE, Ojukwu IC, Novembre FJ, Dewhurst S. (1999). Pathogenesis of simian immunodeficiency virus infection. J Gen Virol, 80 (Pt 7), 1557–1568.
  • White NJ, Webster RG, Govorkova EA, Uyeki TM. (2009). What is the optimal therapy for patients with H5N1 influenza? PLoS Med, 6, e1000091.
  • Wiener AS, Socha WW, Moor-Jankowski J. (1974). Homologous of the human A-B-O blood groups in apes and monkeys. Haematologia (Budap), 8, 195–216.
  • Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. (2011). Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol Cell Biol, 89, 367–374.
  • Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, Gonzalez EJ, Yant LJ, Maness NJ, May GE, Soma T, Reynolds MR, Rakasz E, Rudersdorf R, McDermott AB, O’Connor DH, Friedrich TC, Allison DB, Patki A, Picker LJ, Burton DR, Lin J, Huang L, Patel D, Heindecker G, Fan J, Citron M, Horton M, Wang F, Liang X, Shiver JW, Casimiro DR, Watkins DI. (2006). Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol, 80, 5875–5885.
  • Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X, Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD, Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG, Erickson S, Allison DB, Piatak M Jr, Lifson JD, Shiver JW, Casimiro DR, Shaw GM, Hahn BH, Watkins DI. (2009). Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol, 83, 6508–6521.
  • Wong SS, Yuen KY. (2008). The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother, 62, 437–441.
  • Wood JS, Robertson JS. (2007). Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respi Viruses, 1, 5–9.
  • Woolhouse ME, Gowtage-Sequeria S. (2005). Host range and emerging and reemerging pathogens. Emerging Infect Dis, 11, 1842–1847.
  • Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, Qian CW, Li JX, Lu JH, Wan ZY, Zheng HY, Yan XG, Meng MJ, Fan JL. (2004). Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett, 95, 139–143.
  • Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, Li Z, Deng P, Zhang J, Zhong N, Ding Y, Jiang Y. (2005). Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis, 41, 1089–1096.
  • Xu Y, Jia Z, Zhou L, Wang L, Li J, Liang Y, Zhao T, Ni B, Wu Y. (2007). Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab’)(2) in macaque. Int Immunopharmacol, 7, 1834–1840.
  • Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, Ito M, Shimizu N, Honda M, Yamamoto N, Fujiwara S. (2008). A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis, 198, 673–682.
  • Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 428, 561–564.
  • Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O’Connor DH, Carrington M, Watkins DI. (2006). The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol, 80, 5074–5077.
  • Yen HL, Monto AS, Webster RG, Govorkova EA. (2005). Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis, 192, 665–672.
  • Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, Douglas A, Hay A, Krauss S, Rehg JE, Hoffmann E, Webster RG. (2007). Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol, 81, 6890–6898.
  • Yeung KS, Meanwell NA. (2007). Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus. Infect Disord Drug Targets, 7, 29–41.
  • Yim KC, Carroll CJ, Tuyama A, Cheshenko N, Carlucci MJ, Porter DD, Prince GA, Herold BC. (2005). The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol, 79, 14632–14639.
  • Yip CW, Hon CC, Shi M, Lam TT, Chow KY, Zeng F, Leung FC. (2009). Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. Infect Genet Evol, 9, 1185–1196.
  • Zhang S, Racaniello VR. (1997). Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. J Virol, 71, 4915–4920.
  • Zhang Y, Li T, Fu L, Yu C, Li Y, Xu X, Wang Y, Ning H, Zhang S, Chen W, Babiuk LA, Chang Z. (2004). Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett, 560, 141–146.
  • Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF. (2008). Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS ONE, 3, e3963.
  • Zhao P, Cao J, Zhao LJ, Qin ZL, Ke JS, Pan W, Ren H, Yu JG, Qi ZT. (2005). Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology, 331, 128–135.
  • Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. (2002). Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol, 76, 4420–4429.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.